Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesDividends payablesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Galectin Therapeutics (GALT) Current Deferred Revenue (2010 - 2012)

Galectin Therapeutics' quarterly Current Deferred Revenue came in at $200000.0 in Q2 2012, little changed year-on-year from $200000.0 in Q3 2011, and little changed quarter-over-quarter from $200000.0 in Q1 2012.

Galectin Therapeutics has reported Current Deferred Revenue for 3 years, with the latest figure at $200000.0 in Q2 2012.

  • For the quarter ending Q2 2012, Current Deferred Revenue changed 0.0% year-over-year to $200000.0; the trailing twelve-month figure through Jun 2012 stood at $200000.0 (changed 0.0% YoY), and the FY2011 full-year result was $200000.0, changed 0.0% from the prior year.
  • Current Deferred Revenue for Q2 2012 stood at $200000.0, roughly flat from $200000.0 in the prior quarter.
  • The five-year high for Current Deferred Revenue was $200000.0 in Q4 2010, with the low at $200000.0 in Q4 2010.
  • Average Current Deferred Revenue over 3 years is $200000.0, with a median of $200000.0 recorded in 2010.
  • Peak annual rise in Current Deferred Revenue reached 0.0% in 2011, while the deepest fall reached 0.0% in 2011.
  • Tracing GALT's Current Deferred Revenue over 3 years: stood at $200000.0 in 2010, then changed by 0.0% to $200000.0 in 2011, then changed by 0.0% to $200000.0 in 2012.
  • The last three Current Deferred Revenue figures came in at $200000.0 (Q2 2012), $200000.0 (Q1 2012), and $200000.0 (Q4 2011), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn -
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn -
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn
7 Evaxion A 64.16 Bn 64.14 Bn -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn
10 Galectin Therapeutics 165.77 Mn 151.67 Mn -

Historic Data

Download Data 🔒
DateValue
Jun 30, 2012 200,000.00
Mar 31, 2012 200,000.00
Dec 31, 2011 200,000.00
Sep 30, 2011 200,000.00
Jun 30, 2011 200,000.00
Dec 31, 2010 200,000.00